Patient Factors & Disease Burden with Tagraxofusp

In this segment, Dr Luskin examines how patient-related factors influence treatment decisions in blastic plasmacytoid dendritic cell neoplasm (BPDCN), a disease that predominantly affects older adults. She discusses the limitations of traditional clinical trial populations, which often emphasize younger and medically fit patients, and highlights the unmet need for effective treatment options for individuals considered “unfit” by conventional standards. Dr Luskin explains why chronological age alone should not be the primary determinant of therapy selection and emphasizes the importance of evaluating physiologic reserve and organ function. The conversation underscores the clinical relevance of achieving complete remission with tagraxofusp across a broad patient population and explores how meaningful responses may allow select patients, regardless of baseline fitness, to proceed to allogeneic stem cell transplantation. Without detailing specific eligibility criteria or treatment pathways, this segment reinforces the importance of individualized assessment and expanded therapeutic opportunities for patients with BPDCN in both community and academic settings.